Showing 1811-1820 of 7669 results for "".
- Leading Melanoma Groups Unveil New Campaign Aimed at Menhttps://practicaldermatology.com/news/20120515-leading_melanoma_groups_unveil_new_campaign_aimed_at_men/2459800/To educate men about the importance of regular skin cancer screenings, the Melanoma International Foundation, Melanoma Research Alliance, Melanoma Research Foundation, and The Skin Cancer Foundation have teamed up with former professional football coach Bill Cowher to help launch Me…
- MELA Sciences Rings in Melanoma Monday with NASDAQ Opening Bellhttps://practicaldermatology.com/news/20120507-mela_sciences_rings_in_melanoma_monday_with_nasdaq_opening_bell/2459807/MELA Sciences, Inc. (NASDAQ: MELA) is kicking off Melanoma/Skin Cancer Detection and Prevention Month by ringing the opening bell for NASDAQ Monday morning. Dr. Doris Day will ring the bell with Dr. Joseph Gulfo, president and CEO of MELA Sciences. MELA Sciences will be supporting the AAD's Mel…
- Celotres Earns CE Mark Approval for Wound Healinghttps://practicaldermatology.com/news/20120504-celotres_earns_ce_mark_approval_for_wound_healing/2459808/European regulators have granted CE Mark approval for Celotres™ hydrogel scaffold from Halscion, Inc. The CE Mark approval was based on the results of a prospective, multi-center, randomized, same-patient controlled, European clinical trial evaluating the efficacy of a single application of Celotre…
- Mylan, Impax Win Ruling in Doryx Generics Patent Casehttps://practicaldermatology.com/news/20120502-mylan_impax_win_ruling_in_doryx_generics_patent_case/2459810/Mylan Inc. (MYL) said it began selling a generic version of the antibiotic Doryx today after a judge ruled it didn't infringe a patent held by Warner Chilcott (WCRX) Plc.
- PhotoMedex Completes Sale of Common Stock for $40 Millionhttps://practicaldermatology.com/news/20120430-photomedex_completes_sale_of_common_stock_for_40_million/2459812/PhotoMedex, Inc. (NasdaqGS: PHMD) expects gross proceeds of $40 million, before deducting underwriting discounts, commissions and other offering expenses, from recent sale of shares of common stock. The company closed concurrent registered offerings of 3,023,432 shares of its common stock at $13.23…
- Lasers May Treat Burn Scars of Military, Civilianshttps://practicaldermatology.com/news/20120420-lasers_may_treat_burn_scars_of_military_civilians/2459817/Fractional laser procedures may offer a treatment option for the estimated 1 million American who survive serious burn injuries each year, according to experts presenting at the ASLMS Annual Meeting in Kissimmee, FL. According to Jill Waibel, MD, credited with performing one of (or perhaps the) fir…
- FDA Seeks More Information on Pliaglishttps://practicaldermatology.com/news/20120419-fda_seeks_more_information_on_pliaglis/2459818/FDA's Complete Response Letter to Galderma Laboratories LP outlines additional information the FDA requires before it will approve the sNDA for Pliaglis, developer Nuvo Research, Inc. reports. The response is to the supplemental New Drug Application (sNDA) for the lidocaine and tetracaine 7%/7% top…
- Amgen, Pfizer Will No Longer Co-Market Enbrelhttps://practicaldermatology.com/news/20120419-amgen_pfizer_will_no_longer_co-market_enbrel/2459819/Amgen and Pfizer will end co-promotion of Enbrel (etanercept) in North America this summer, the companies tell the Wall Street Journal. Amgen will assume full marketing responsibilities in the US, effective July 23.
- Botox Reaches 10-Year Milestone in Aestheticshttps://practicaldermatology.com/news/20120416-botox_reaches_10-year_milestone_in_aesthetics/2459824/Allergan, Inc. marked the 10-year anniversary of the FDA approval of Botox Cosmetic (onabotulinumtoxinA) to improve the look of moderate to severe frown lines between the eyebrows in patients age 18-65.In the decade since Botox Cosmetic was approved, aesthetic specialty physicians have performed ap…
- Valeant Headquarters Moving to Montreal Regionhttps://practicaldermatology.com/news/20120416-valeant_headquarters_moving_to_montreal_region/2459825/Valeant Pharmaceuticals is relocating its global headquarters to the Montreal region and will establish the Laboratore Dr. Renaud Centre of Excellence—a R&D center for consumer dermatology—in Laval, Quebec. Laboratoire Dr. Renaud and a newly acquired manufacturing facility will function as critical…